Actinium Pharmaceuticals (ATNM) said Tuesday it is launching a clinical program consisting of trials studying Actimab-A in combination with either Merck's (MRK) Keytruda or Bristol Myers Squibb's (BMY) Opdivo for the treatment of multiple solid tumors.
Actimab-A is meant to improve the efficacy of the immunotherapies by targeting myeloid derived suppressor cells, the company said.
The Actimab-A trials will include several controlled, head-to-head studies that will evaluate the combination of Actimab-A with Keytruda and Opdivo in comparison with the two drugs alone.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.